Eran Ophir

Chief Executive Officer at COMPUGEN LTD.

Net worth: 26 731 $ as of 2026-07-30

Consumer Services

Health Technology

Technology Services

Profile

Eran Ophir is the founder of Compugen USA, Inc. Dr. Ophir is currently President, Chief Executive Officer & Director at Compugen Ltd. since 2025.
Education includes an undergraduate degree from Tel-Aviv University and a doctorate from the Weizmann Institute of Science.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
COMPUGEN LTD. 0.01%	2026-07-28	11,375 ( 0.01% )	26 731 $	2026-07-30

Eran Ophir active positions

Companies	Position	Start
COMPUGEN LTD.	Chief Executive Officer	2025-09-22
Compugen Usa, Inc. Compugen Usa, Inc. Information Technology ServicesTechnology Services The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies.	Chief Executive Officer	-

All active positions of Eran Ophir

Training of Eran Ophir

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Eran Ophir's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Compugen Ltd. Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics	Health Technology
Tel-Aviv University Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Weizmann Institute of Science Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Compugen Usa, Inc. Compugen Usa, Inc. Information Technology ServicesTechnology Services The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies.	Technology Services